Myricetin vs Quercetin

Myricetin wins for: broad-spectrum glucose disposal, liver stress mitigation during oral-heavy cycles, secondary stacking as a metabolic workhorse, and lower risk of CYP drug-drug interactions at practical doses. Its α-glucosidase inhibition rounds out GDA stacks without pushing interactions past clinical thresholds, and it's easy to source in bulk for daily use.

Quercetin wins for: high-potency senolytic effects (when paired with dasatinib, or dosed as a pulse), mast-cell/allergy blocking, and real systemic anti-inflammatory impact. Its oral bioavailability is massively improved in phytosome form, and the evidence for intermittent, high-dose protocols in longevity, allergy, and inflammation use cases is more robust. It's the only one of the two with hard literature backing for senescent cell clearance and chronic inflammatory suppression.

Pick Myricetin if:

• The protocol requires glucose disposal support with minimal risk of CYP-mediated drug interactions.
• Stacking as a secondary ingredient with berberine, R-ALA, or metformin in a GDA or longevity blend.
• Supporting liver resilience and reducing oxidative stress on oral-heavy AAS or prohormone cycles.
• Expanding the mechanism mix for metabolic health stacks targeting both pre-meal blood glucose and long-term insulin signaling.
• Sourcing constraints require high-dosage, cost-effective bulk flavonol.

Pick Quercetin if:

• The goal is senolytic activity — specifically, D+Q monthly pulses for anti-aging or tissue rejuvenation.
• Managing histamine-related issues, allergies, or mast cell activation is needed alongside cycle support or looksmaxxing stacks.
• Targeting down-regulation of chronic NF-κB inflammation and immune overactivity, esp. concurrent with AAS.
• A potent phytosome-form option is accessible to maximize oral bioavailability for daily or pulsed protocols.
• Seeking robust literature support for longevity, cardiovascular, or anti-inflammatory outcomes beyond metabolic optimization.